Drug Profile
Research programme: hepatitis C therapeutics - Vironexx
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Vironexx
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Hepatitis C in France (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hepatitis-C in France (Parenteral)
- 05 Jul 2016 Preclinical trials in Hepatitis C in France (Parenteral)